Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas

Area of Science:

• Neuro-oncology
• Immunology
• Cancer Biology

Background:

• Innate immune system stimulation is a potential glioma treatment.
• ATRX mutations in IDH-mutant astrocytomas are linked to immune dysfunction.
• The interaction between ATRX loss and IDH mutation in innate immunity is unclear.

Purpose of the Study:

• To investigate the combined effects of ATRX loss and IDH1^R132H mutation on innate immunity in glioma.
• To explore the therapeutic potential of targeting innate immunity in astrocytomas.

Main Methods:

• Generated ATRX-deficient glioma models with and without IDH1^R132H mutation.
• Assessed sensitivity to dsRNA-based innate immune agonism.
• Evaluated in vivo lethality and T-cell infiltration.
• Investigated the impact of IDH1^R132H on immune gene expression and the effect of its inhibition.

Main Results:

• ATRX-deficient glioma cells showed sensitivity to dsRNA agonism, with impaired lethality and increased T-cell infiltration in vivo.
• IDH1^R132H mutation suppressed baseline innate immune gene and cytokine expression.
• Genetic and pharmacological inhibition of IDH1^R132H restored immune gene expression.
• IDH1^R132H did not impede ATRX deficiency-driven dsRNA sensitivity.
• ATRX loss primes cells for dsRNA recognition, which is reversibly masked by IDH1^R132H.

Conclusions:

• ATRX loss sensitizes astrocytomas to dsRNA-based immune stimulation.
• IDH1^R132H mutation reversibly inhibits this innate immune priming.
• Innate immunity represents a therapeutic vulnerability in astrocytomas.